You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《滬深兩市》A股三大指數半日跌0.2%至0.6% 內房股走弱 以嶺藥業續升2.9%
內地昨日(15日)新增本土確診病例1,568例,新增本土無症狀感染者18,491例。人行今日(16日)開展710億元人民幣(下同)7天期逆回購操作,單日淨投放630億元。人民幣兌美元中間價今上調58點。上月內地70城市房價跌幅擴大,A股三大指數微微低開後反覆偏軟。 上證半日跌6點或0.2%,收報3,127點;深成指跌61點或0.6%,收報11,289點;創業板指數跌14點或0.6%,收報2,417點。上證、深成及創板半日成交分別為2,523億元、3,685億元及1,338億元。 中資金融股工行(601398.SH)平收。建行(601939.SH)跌0.4%。國壽(601628.SH)跌1.5%。 內房股走弱,金地(600383.SH)、萬科(000002.SZ)、保利發展(600048.SH)、華夏幸福(600340.SH)及陽光城(000671.SZ)跌3.1%至5.2%。新城控股(601155.SH)挫9.2%。 比亞迪(002594.SZ)跌1.8%。寧德時代(300750.SZ)跌2.5%。 以嶺藥業(002603.SZ)連續兩日升停後,今早續升2.9%,內媒報道指石家莊市前日(14日)公布取消全員核酸檢測,當地居民憂慮疫情爆發,以嶺藥業總部所在地石家莊部分藥店,包括連花清瘟膠囊等抗疫感冒藥已售罄。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account